Overcoming Immunosuppression: The Role of Tumor- Infiltrating Tregs and Their Key Target CCR8 in Immunotherapy Resistance and Therapeutic Strategies
Main Article Content
Keywords
CCR8, tumor-infiltrating regulatory T cells, immunotherapy resistance, tumor microenvironment, immunotherapy
Abstract
The immunosuppressive tumor microenvironment (TME), orchestrated largely by tumor -infiltrating regulatory T cells (TI -Tregs), represents a critical barrier to effective cancer immunotherapy. This review focuses on the chemokine receptor CCR8, which has recently emerged as a highly promising and specific target for therapeutic intervention due to its preferential and stable expression on highly suppressive TI -Treg subsets. We synthesize current evidence demonstrating that CCR8 is selectively upregulated on TI -Tregs across multiple solid tumor types, where its expression correlates with poor patient prognosis and resistance to immune checkpoint inhibitors (ICIs). This expression pattern —enriched within the tumor but minimal in peripheral blood and normal tissues —provides a compelling rationale for tumor -selective targeting. We critically examine the primary therapeutic strategies under development, including ADCC -enhanced monoclonal antibodies, which have shown the most clinical promise, alongside bispecific antibodies and small molecule antagonists. While early -phase clinical trials report encouraging safety and on -target pharmacodynamic activity, the field faces significant challenges. These include unresolved questions regarding CCR8's functional role versus its value as a targeting biomarker, a lack of validated predictive biomarkers for patient stratification, and the physical barriers to effective drug delivery in solid tumors. This review aims to provide a comprehensive and nuanced understanding of CCR8 biology and to outline the key steps necessary for the successful clinical translation of CCR8-targeted therapies.
References
- [1] Van Damme, H., Dombrecht, B., Kiss, M., Roose, H., Allen, E., Van Overmeire, E., Kancheva, D., Martens, L., Murgaski, A., Bardet, P. M. R., Blancke, G., Jans, M., Bolli, E., Martins, M. S., Elkrim, Y., Dooley, J., Boon, L., Schwarze, J. K., Tacke, F., Movahedi, K., … Van Ginderachter, J . A. (2021). Therapeutic depletion of CCR8+ tumor-infiltrating regulatory T cells elicits antitumor immunity and synergizes with anti -PD-1 therapy. Journal for immunotherapy of cancer, 9(2), e001749. https://doi.org/10.1136/jitc-2020-001749
- [2] Roider, H. G., Hoff, S., Tseng, S. Y., Berndt, S., Trautwein, M., Filarsky, K., Gritzan, U., Camps, J., Nadler, W. M., Grudzinska -Goebel, J., Ellinger, P., Pesch, T., Soon, C. F., Geyer, M., Gluske, K., Stelte-Ludwig, B., & Gorjá ná cz, M. (2024). Selective depletion of tumor-infiltrating regulatory T cells with BAY 3375968, a novel Fc -optimized anti -CCR8 antibody. Clinical and experimental medicine, 24(1), 122. https://doi.org/10.1007/s10238-024-01362-8
- [3] Nagira, Y., Nagira, M., Nagai, R., Nogami, W., Hirata, M., Ueyama, A., Yoshida, T., Yoshikawa, M., Shinonome, S., Yoshida, H., Haruna, M., Miwa, H., Chatani, N., Ohkura, N., Wada, H., & Tanaka, H. (2023). S-531011, a Novel Anti -Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor -Infiltrating CCR8 -Expressing Regulatory T Cells. Molecular cancer therapeutics, 22(9), 1063–1072. https://doi.org/10.1158/1535-7163.MCT-22-0570
- [4] Tian, B., Wang, Z., Cao, M., Wang, N., Jia, X., Zhang, Y., Zhou, J., Liu, S., Zhang, W., Dong, X., Li, Z., Xue, J., Wang, J., Fan, G. H., & Li, Q. (2025). CCR8 antagonist suppresses liver cancer p rogression via turning tumor -infiltrating Tregs into less immunosuppressive phenotype. Journal of experimental & clinical cancer research : CR, 44(1), 113. https://doi.org/10.1186/s13046-025-03286-x
- [5] Whiteside, S. K., Grant, F. M., Gyori, D. S., Conti, A. G., Imianowski, C. J., Kuo, P., Nasrallah, R., Sadiyah, F., Lira, S. A., Tacke, F., Eil, R. L., Burton, O. T., Dooley, J., Liston, A., Okkenhaug, K., Yang, J., & Roychoudhuri, R. (2021). CCR8 mark s highly suppressive Treg cells within tumours but is dispensable for their accumulation and suppressive function. Immunology,163(4),512 -520. https://doi.org/10.1111/imm.13337
- [6] Kidani, Y., Nogami, W., Yasumizu, Y., Kawashima, A., Tanaka, A., Sonoda, Y., Tona, Y., Nashiki, K., Matsumoto, R., Hagiwara, M., Osaki, M., Dohi, K., Kanazawa, T., Ueyama, A., Yoshikawa, M., Yoshida, T., Matsumoto, M., Hojo, K., Shinonome, S., Yoshida, H., … Sakaguchi, S. (2022). CCR 8- targeted specific depletion of clonally expanded Treg cells in tumor tissues evokes potent tumor immunity with long -lasting memory. Proceedings of the National Academy of Sciences of the United States of America, 119(7), e2114282119. https://doi.org/10.1073/pnas.2114282119
- [7] Guo, C., Dai, X., Du, Y., Xiong, X., & Gui, X. (2024). Preclinical development of a novel CCR8/CTLA-4 bispecific antibody for cancer treatment by disrupting CTLA -4 signaling on C D8 T cells and specifically depleting tumor -resident Tregs. Cancer immunology,immunotherapy :CII,73(10),210. https://doi.org/10.1007/s00262-024-03794-3
- [8] Gampa, G., Spinosa, P., Getz, J., Zhong, Y., Halpern, W., Esen, E., Davies, J., Chou, C., Kwong, M., Wang, Y., Arenzana, T. L., Shivva, V., Huseni, M., Hsieh, R., Schartner, J., Koerber, J. T., Rutz, S., & Hosseini, I. (2024). Preclinical and translational pharmacology of afucosylated anti -CCR8 antibody for depletion of tumour-infiltrating regulatory T cells. British journal of pharmacology, 181(13), 2033–2052. https://doi.org/10.1111/bph.16326
- [9] Liu, L., Rangan, L., Vanalken, N., Kong, Q., Schlenner, S., De Jonghe, S., Schols, D., & Van Loy, T. (2024). Development of a cellular model to study CCR8 signaling in tumor -infiltrating regulatory T cells. Cancer immunology, immunotherapy : CII, 73(1), 11. https://doi.org/10.1007/s00262-023-03607- z
- [10] Delacher, M., Simon, M., Sanderink, L., Hotz -Wagenblatt, A., Wuttke, M., Schambeck, K., Schmidleithner, L., Bittner, S., Pant, A., Ritter, U., Hehlgans, T., Riegel, D., Schneider, V., Groeber - Becker, F. K., Eigenberger, A., Gebhard, C., Strieder, N., Fischer, A., Rehli, M., Hoffmann, P., … Feuerer, M. (2021). Single -cell chromatin accessibility landscape identifies tissue repair program in human regulatory T cells. Immunity, 54(4), 702–720.e17. https://doi.org/10.1016/j.immuni.2021.03.007
- [11] Weaver, J. D., Stack, E. C., Buggé , J. A., Hu, C., McGrath, L., Mueller, A., Wong, M., Klebanov, B., Rahman, T., Kaufman, R., Fregeau, C., Spaulding, V., Priess, M., Legendre, K., Jaffe, S., Upadhyay, D., Singh, A., Xu, C. A., Krukenberg, K., Zhang, Y., … Gostissa, M. (2022). Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor -infiltrating T regulatory cells by GS -1811, a novel Fc -optimized anti -CCR8 antibody. Oncoimmunology, 11(1), 2141007. https://doi.org/10.1080/2162402X.2022.2141007
- [12] Wang, X., Kapoor, V. N., Chin, D. J., Klakamp, S. L., Baruffaldi, F., Mohan, J. F., Haines, R., Dulak, A., Panduro, M., Ren, Y., Masia, R., Hill, J. A., LaVallee, T. M., & Rajasekaran, N. (2025). CHS -114: an afucosylated anti -CCR8 monoclonal antibody that selectively depletes intratumoral Treg cells and induces antitumor immune responses. Molecular cancer therapeutics, 10.1158/1535-7163.MCT-25-0367. Advance online publication. https://doi.org/10.1158/1535-7163.MCT-25-0367
- [13] Cadilha, B. L., Benmebarek, M. R., Dorman, K., Oner, A., Lorenzini, T., Obeck, H., Vä nttinen, M., Di Pilato, M., Pruessmann, J. N., Stoiber, S., Huynh, D., Mä rkl, F., Seifert, M., Manske, K., Suarez - Gosalvez, J., Zeng, Y., Lesch, S., Karches, C. H., H eise, C., Gottschlich, A., … Kobold, S. (2021). Combined tumor -directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors. Science advances,7(24),eabi5781. https://doi.org/10.1126/sciadv.abi5781
- [14] Sun, T., Liu, B., Li, Y., Wu, J., Cao, Y., Yang, S., Tan, H., Cai, L., Zhang, S., Qi, X., Yu, D., & Yang, W. (2023). Oxamate enhances the efficacy of CAR -T therapy against glioblastoma via suppressing ectonucleotidases and CCR8 lactylation. Journal of experimental & clinical cancer research :CR,42(1),253. https://doi.org/10.1186/s13046-023-02815-w
Article Sidebar
This work is licensed under a Creative Commons Attribution 4.0 International License.